EARLY PHASE CLINICAL TRIALS

Accelerate your early phase clinical trial decisions

Rising cost pressures, uncertainties and complexities require faster, better-informed early phase decisions to improve efficient program progression decisions. IQVIA’s deep expertise in customized adaptive-design concepts expedites delivery even in the most complex studies — with access to diverse sites, healthy volunteers, and patients virtually anywhere in the world. 

Contact Us
Solutions Research & Development Early Phase Clinical Trials

Industry-leading early phase design strategies and delivery — customized for your molecule

With more than 43 years of deep experience in Phase I/II trials, IQVIA empowers you with faster, better-informed decisions from First-in-Human to Phase IIa — through our best-in-class custom designs and vast global site network.

PHASE I EXPERTISE
536

Phase I studies over the past 5 years in 28,122 subjects across 67 countries

FIRST IN HUMAN STUDIES
151

First-in-human studies over the past 5 years in 13,038 subjects across 48 countries

HEALTHY VOLUNTEERS
327

Phase I studies over the past 5 years in 14,012 healthy adult volunteers across 48 countries

A faster path for your molecule amid today’s uncertainties and challenges

Global drug development expertise

IQVIA brings you specialized expertise in successful early phase design strategies and delivery—bolstered by more than 15 Therapeutic and Specialty Centers of Excellence across a breadth of medical domains.

Best-in-class Phase I hybrid designs

Let IQVIA help you customize your adaptive-design protocol to accelerate delivery — and ensure safety and quality — even in the most complex studies and populations.

Site network spanning 6 continents

Diverse, therapeutically aligned sites across 80 countries — including critical geographical regions. Work with IQVIA’s in-house site in the UK, selective network of trusted partner sites, and 3rd party sites.

Seamless transition from early- to late-stage trials

Expedite molecule advancement with IQVIA’s integrated phase I-IIa delivery model that retains institutional knowledge and maximizes efficiency and continuity — with one SOP, one platform and one project manager.

Ensure the optimal site selection for your molecule
IQVIA’s global Phase I site network includes our own hospital-based clinical research unit, offering you an extensive range of therapeutically aligned site options in key regions (such as APAC and Australia). Each carefully-selected site brings expertise in regulatory pathways, accelerated titration and BOIN designs, PK/PD modeling, receptor occupancy, immunologic pathways, and a full breadth of Phase I services. Each also undergoes rigorous quality controls and inspections, and benefits from well-established relationships that maximize efficiency and quality.
Futuristic world map

41

PHASE I GxP – MEDICALLY QUALIFIED IN-NETWORK SITES

15

THERAPEUTIC & SPECIALTY CENTERS OF EXCELLENCE

2,424

EARLY PHASE BED CAPACITY WORLDWIDE

>116

EARLY PHASE PROJECT MANAGERS

>2300

MONITORS WITH EARLY PHASE EXPERIENCE

NEW PERSPECTIVES IN EARLY PHASE RESEARCH

Blog
The New Reality of Early Phase Clinical Trials
By: Elizabeth Allen, Raymond Cook, Joanne Emanuel, Jochen Zeschky
White Paper
Optimizing Early-Phase Clinical Trials for Rapid, Evidence-Based Decision Making
Fact Sheet
Expedite Your Early Phase Clinical Trial Decisions
White Paper
Concentration-QT Modeling: An Efficient Alternative for Clinical Development
White Paper
Inclusion of Obese Individuals in Early Phase Healthy Volunteer Trials
White Paper
Paradigm Shifts in Early Phase Non-Oncology Studies in Healthy Volunteers and Patients
Prev
Next

Related solutions

Therapeutic & Specialty Expertise

Specialized expertise and customized solutions across 14 therapeutic centers of excellence, including oncology, GI/NASH, pediatrics, neurology and rare diseases.

Oncology & Hematology

Focus oncology development on the patient, manage trial complexity, and increase predictability and speed.

Biosimilars

Bring your biosimilar to market faster by tapping into unparalleled data, technology, advanced analytics, and scientific expertise.

Rare Diseases

Build on our experience of more than 245 rare disease studies in 96 countries to fulfill your promise of hope to millions around the world.

Contact Us